Objective: Thrombocytopenia, expressed as platelet counts lower than 150 × 10 9 /L, is a common hematological anomaly seen in 6.6% of the pregnancies. Incidental thrombocytopenia of the pregnancy, commonly referred to as gestational thrombocytopenia, accounts for 70%-80% of cases. This study aimed to elucidate the effect of gestational thrombocytopenia on negative fetal and maternal results in low-risk pregnancies. Method: The patients were divided into two groups. The control group (n = 240) consisted of healthy pregnant women with normal platelet count, and the study group (n = 80) consisted of pregnant women with gestational thrombocytopenia. Results: Maternal age, pre-pregnancy body mass indexes, parity, and previous cesarean history rates were similar in both groups. Gestational age during delivery, fetal weight, delivery induction, amniotic fluid stained with meconium, hyperbilirubinemia, admission to neonatal intensive care unit, transient tachypnea of the newborn, respiratory distress syndrome, hypoxicischemic encephalopathy, necrotizing enterocolitis, intraventricular hemorrhage, and 5-min Apgar scores of <7 were not different between the groups (P = 0.056, P = 0.233, P = 0.582, P = 0.798, P = 0.711, P = 0.859, P = 0.634, P = 1, P = 1,P = 1, P = 1,and P = 1, respectively). Spontaneous vaginal delivery, necessity for emergency cesarean delivery, postpartum hemorrhage, abnormal hemorrhage during cesarean, necessity for blood transfusion, and postpartum hysterectomy rates did not differ between the groups (P = 0.530, P = 0.752, P<0.001, P<0.001, P = 0.758, P = 1, P = 1,and P = 1, respectively). Despite being within normal limits, discharge time after C/S and spontaneous vaginal delivery was longer in the gestational thrombocytopenia group than in the control group.
INTRODUCTION
Thrombocytopenia, expressed as a platelet count of less than 150 × 10 9 /L, is a common hematological abnormality in pregnancy with an incidence of 6.6%. 1 Incidental thrombocytopenia of the pregnancy, commonly referred to as gestational thrombocytopenia, accounts for 70%-80% of cases 1 . The pathogenesis of the abnormality is uncertain, but the causes of gestational thrombocytopenia may be a number of medical conditions such as hemodilution and increased destruction 2 . Gestational thrombocytopenia has several characteristics 3 . The first one of these is the appearance between the middle of the second trimester and the third trimester. In most of these cases, the platelet count is higher than 75  10 9 /L 4, 5 . The second is that women with gestational thrombocytopenia are asymptomatic and have no hemorrhage history. The third is that the women had no thrombocytopenia history except during pregnancy. The fourth is that the number of platelets usually returns to normal in 1-2 months after postpartum 6 .
Thrombocytopenia is classified as mild when the platelet count is in the 100-150 × 10 9 /L range, moderate when it is in the 50-100 × 10 9 /L range, and severe when it is lower than 50 × 10 9 /L. Mild thrombocytopenia is the most common platelet disorder during pregnancy. Moderate and severe thrombocytopenia is observed in only 1% of pregnant women 5 . Severe thrombocytopenia during pregnancy increases the risk of postpartum hemorrhage, neonatal asphyxia, and neonatal thrombocytopenia 7 .
In current clinical practice, gestational thrombocytopenia remains a source of concern for both the mother and the obstetrician, although negative maternal and fetal outcomes occur in the presence of severe thrombocytopenia. Thus, this study aimed to clarify the effect of gestational thrombocytopenia on negative fetal and maternal outcomes in low-risk pregnancies.
MATERIAL AND METHODS
This retrospective study was conducted by scanning the results of the pregnant women matching the criteria of the study between January 2016 and June 2018. It included pregnant women aged 18-35 years having singleton gestation, who gave birth in Sivas Sarkisla Government Hospital and whose platelet counts were at the level of 75-150 10 9 /L in their full blood count during 37-41 weeks of pregnancy. This study was approved by the ethics committee of the Cumhuriyet University on the basis of the Helsinki Declaration (approval number: 2018-05/18).
Patients with multiple pregnancies, gestational diabetes, type 1 and type 2 diabetes, preeclampsia, gestational hypertension, chronic hypertension, presence of a fetal anomaly, presence of a chromosome anomaly, smoking, and alcohol use, and chronic liver, kidney, and heart diseases were excluded from the study.
In addition, patients having a history of HELLP (hemolysis (H), elevated liver enzymes (EL) and low platelet count (LP)) syndrome, primary immune thrombocytopenia, antiphospholipid antibody syndrome, systemic lupus syndrome, human immunodeficiency virus (HIV), hepatitis C, cytomegalovirus, Helicobacter pylori, disseminated intravascular coagulopathy, thrombotic thrombocytopenia, hemolytic uremic syndrome, bone marrow diseases, nutritional deficiencies, and congenital thrombocytopenia that might cause thrombocytopenia in pregnancy were excluded from the study 8 .
The patients were divided into two groups. The control group (n = 240) consisted of healthy pregnant women with normal platelet count, and the study group (n = 80) consisted of pregnant women with gestational thrombocytopenia.
The cases having platelet counts in the range 75-150 × 10 9 /L were determined as gestational thrombocytopenia, and other factors leading to thrombocytopenia during pregnancy were excluded during this identification.
Demographic data such as age, gravida, parity, body mass index (kg/m 2 ), and previous cesarean history were recorded. Negative perinatal outcomes were defined as the presence of any of the following: 5-min Apgar <7, transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), amniotic fluid stained with meconium, admission to neonatal intensive care unit (NICU), hyperbilirubinemia, hypoxicischemic encephalopathy (HIE), intraventricular hemorrhage (IVH), and neonatal death 9 . Postpartum hemorrhage was defined as>500 mL blood loss at vaginal birth and>1000 mL at cesarean delivery 10 .
The Minitab16 statistical software was used to perform statistical analysis (Minitab Inc., PA, USA). The Shapiro-Wilk test was used to assess the normality of the data, and the Levene test was used to assess the homogeneity of the variances. Values were expressed as mean ± standard deviation. Parametric comparisons were made using the t-test or z test. Nonparametric comparisons were made using the Mann-Whitney U test. A P value <0.05 was considered significant.
RESULTS
Of the 320 pregnant women included in the study, 80 belonged to the gestational thrombocytopenia group, and 240 belonged to the control group. Table 1 shows the comparisons of demographic and obstetric characteristics. Maternal age (P = 0.322), pre-pregnancy BMI (P = 0.057), gravida (P = 0.799), parity (P = 0.979), and previous cesarean delivery rates (P = 0.662) were similar in both groups. Table 2 shows the fetal results. The gestational age at delivery, fetal weight, delivery induction, amniotic fluid stained with meconium, hyperbilirubinemia, NICU admission, TTN, RDS, HIE, NEC, IVH, 5-min Apgar scores of <7, and neonatal death results were not significantly different between the groups (P = 0.056, P = 0.233, P = 0.582, P = 0.798, P = 0.711, P = 0.859, P = 0.634, P = 1, P = 1, P = 1, P = 1, and P = 1, respectively). 0 (0%) 0 (0%) 1 IVH, n (%) 0 (0%) 0 (0%) 1 Neonatal death, n (%) 0 (0%) 0 (0%) 1 Table 3 shows the maternal results. Spontaneous vaginal delivery, emergency cesarean section necessity, postpartum hemorrhage, abnormal hemorrhage during cesarean section, necessity for blood transfusion, and postpartum hysterectomy were not significantly different between the groups (P = 0.530, P = 0.752, P<0.001, P<0.001, P = 0.758, P = 1, P = 1, and P = 1, respectively). Despite being within normal limits, discharge time after cesarean and spontaneous vaginal delivery was longer in the gestational thrombocytopenia group than in the control group. 
DISCUSSION
This study aimed to elucidate the effect of gestational thrombocytopenia on negative fetal and maternal outcomes in low-risk pregnancies. The results showed that gestational thrombocytopenia did not increase the risk of negative perinatal outcomes for both the mother and the fetus in lowrisk pregnancies.
Clinicians often face thrombocytopenic pregnancies in a routine clinical examination. Clinicians can effectively manage thrombocytopenic pregnancies if the cause of the disease is diagnosed before delivery or during delivery, but a definitive thrombocytopenia diagnosis for many obstetric patients is only performed after delivery. This creates a challenge for clinicians in designing a safe plan for delivery. The presence or absence of an underlying disease that causes or accompanies thrombocytopenia at this point is the main determinant of maternal and fetal outcomes.
The results of this study showed that gestational thrombocytopenia is not a risk factor for negative fetal and maternal outcomes. These positive results could be explained by the absence of risk factors or diseases that affect platelet function and counting. Various studies in the literature have evaluated gestational thrombocytopenia and its effects on the mother and fetus. Similarly, a prospective cohort study performed by Burrows and Kelton on 756 females showed that gestational thrombocytopenia was not associated with any hemorrhage complications 1 . In another study, Levy and Murphy found that mild gestational thrombocytopenia had no negative effects on the fetus, newborn, and mother 11 . In a recently published study, Ying-Hsven Lin et al. reported that incidental thrombocytopenia in low-risk pregnancies is not an increased risk factor for negative perinatal outcomes during delivery 10 . Finally, in 2016, the ACOG study bulletin reported that women with gestational thrombocytopenia did not pose a risk for maternal or fetal hemorrhage or bleeding complications 8 .
In the birth statistics of Turkey, it is reported that 1,291,055 live births occurred in 2017 12 . When the incidence rate of gestational thrombocytopenia (6.6%) is considered, approximately 85,000 gestational thrombocytopenia cases per year are encountered in Turkey. When the clinicians consult these patients, they can tell the patient and her family that no risk exists for the mother and the baby, vaginal delivery and cesarean operations can be performed safely, and they should not be concerned about this situation.
CONCLUSION
The findings of this study indicated that gestation thrombocytopenia did not increase the risk of a negative perinatal outcome for both the mother and the fetus in low-risk pregnancies.
